Shopping Cart
- Remove All
- Your shopping cart is currently empty
ST 2825 is a specific MyD88 dimerization inhibitor that blocks IL-1β-mediated activation of NF-κB transcriptional activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,970 | 8-10 weeks | |
50 mg | $2,580 | 8-10 weeks | |
100 mg | $3,400 | 8-10 weeks |
Description | ST 2825 is a specific MyD88 dimerization inhibitor that blocks IL-1β-mediated activation of NF-κB transcriptional activity. |
In vitro | ST2825 inhibits IL-1R/TLR signaling by disrupting MyD88 homodimerization in a concentration-dependent manner, achieving approximately 40% inhibition at 5 μM and 80% inhibition at 10 μM ST2825 [1]. |
In vivo | ST2825 effectively reduces IL-1β-induced IL-6 production in mice through oral administration, showing significant inhibition at 100 and 200 mg/kg doses. Mice receive oral doses of ST2825 or vehicles, ranging from 50 to 200 mg/kg, five minutes before intraperitoneal (i.p.) injections of 20 μg/kg IL-1β [1]. |
Molecular Weight | 591.51 |
Formula | C27H28Cl2N4O5S |
Cas No. | 894787-30-5 |
Relative Density. | 1.51 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (169.06 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.